白细胞介素-6,生物制剂,皮肤病,托珠单抗," /> 白细胞介素-6,生物制剂,皮肤病,托珠单抗,"/> interleukin-6, biological agent, skin disease, tocilizumab,"/> <span style="font-size:12px;">IL-6/IL-6R抑制剂在免疫炎症性皮肤疾病的应用</span>

中国麻风皮肤病杂志 ›› 2024, Vol. 40 ›› Issue (2): 145-149.doi: 10.12144/zgmfskin202402145

• 综述 • 上一篇    下一篇

IL-6/IL-6R抑制剂在免疫炎症性皮肤疾病的应用

蒋卓育,王宇嘉,张悦,江燕云,王亮春   

  1. 中山大学孙逸仙纪念医院皮肤科，广东广州，510120
  • 出版日期:2024-02-15 发布日期:2024-01-31

Application of IL-6/IL-6R inhibitors in immunoinflammatory skin diseases

JIANG Zhuoyu, WANG Yujia, ZHANG Yue, JIANG Yanyun, WANG Liangchun   

  1. Department of Dermatology, Hospital of Sun Yat-Sen Memorial, University of Sun Yat-Sen, Guangzhou 510120, China
  • Online:2024-02-15 Published:2024-01-31

PDF (PC)

127

摘要： 白细胞介素-6（IL-6）是一种前炎症因子，与细胞表面受体或细胞外可溶性受体结合后，激活多种信号通路，通过调节免疫炎症细胞的增殖、分化和功能，而参与多种皮肤疾病的发生、发展。近年来，IL-6/IL-6受体（IL-6R）抑制剂在皮肤病领域的应用引起了广泛关注，尤其是最早上市的托珠单抗（Tocilizumab, TCZ），在治疗系统性硬化症、成人still病、白塞病、系统性红斑狼疮、银屑病关节炎、特应性皮炎等疾病中有一定疗效。本文就IL-6/IL-6R抑制剂，尤其是TCZ在皮肤科疾病治疗中的应用，包括疗效、安全性和不良反应进行综述，以了解其应用现状并展望其应用前景。

关键词: 白细胞介素-6')">">白细胞介素-6, 生物制剂, 皮肤病, 托珠单抗

Abstract: Interleukin-6 (IL-6) is a proinflammatory cytokine that combines IL-6 receptor (IL-6R) on cells surface and soluble IL-6R(sIL-6R) as well to activate various signaling pathways. It participates the pathophysiological processes of various skin diseases by regulating the proliferation, differentiation and function of inflammatory cells. In recent years, IL-6/IL-6R inhibitors, especially Tocilizuma has been used to treat skin diseases such as systemic sclerosis, adult-onset still’s disease, Bechet’s Disease, systemic lupus erythematosus, psoriatic arthritis, atopic dermatitis and so on. We here briefly outlined the signaling pathway and reviewed the efficacy and safety of Tocilizuma reported in clinical trials and case studies, to highlight a promising therapeutic option for some refractory immune related skin diseases.

Key words: interleukin-6')">">interleukin-6, biological agent, skin disease, tocilizumab